CTAD as a Universal Anticoagulant
Author Information
Author(s): M. Yokota, N. Tatsumi, I. Tsuda, T. Nishioka, T. Takubo
Primary Institution: Osaka City University Medical School
Hypothesis
Can CTAD be used as a new anticoagulant for medical laboratory use?
Conclusion
CTAD is an excellent candidate for a new anticoagulant usable for simultaneous evaluation of haematological, biochemical, and coagulation items in the routine laboratory.
Supporting Evidence
- CTAD blood showed results similar to EDTA blood in complete blood count tests.
- CTAD plasma exhibited high correlation with citrate plasma in coagulation tests.
- CTAD allows for reduced blood volume in laboratory testing.
Takeaway
CTAD is a new type of blood thinner that helps doctors run tests on blood without needing a lot of it.
Methodology
The study involved comparing blood tests using CTAD with those using EDTA and citrate in a controlled laboratory setting.
Limitations
CTAD blood cannot provide accurate data for sodium and chlorine due to the sodium ion in the CTAD solution.
Participant Demographics
Adult healthy donors aged 25-47 years.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website